Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06427460
PHASE2

Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)

Sponsor: Changhai Hospital

View on ClinicalTrials.gov

Summary

In the case of large tumors or tumors closely adjacent to organs at risk, ablative doses offered by stereotactic body radiation therapy (SBRT) could not be delivered. Therefore, a technique that could provide high radiation doses to tumors without increasing of risks of severe adverse effects is required.

Official title: Central-boost Ablative Radiation Therapy for Large Tumors or Tumors Adjacent to Organs at Risk

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

67

Start Date

2024-05-12

Completion Date

2026-12-31

Last Updated

2024-05-23

Healthy Volunteers

No

Interventions

RADIATION

Central-boost ablative dose delivered by stereotactic body radiation therapy

An inner and complete gross tumor volume (iGTV) is created within the gross tumor volume (GTV). For the liver or lung tumor, the convetional radiation dose is 35-45Gy/5f. Regarding the pancreatic tumor or retroperitoneal tumor, the radiation dose is 30-40Gy/5f. Hence, the radiation dose of iGTV should not be less than 120% of the dose of GTV.

Locations (1)

Huojun Zhang

Shanghai, Shanghai Municipality, China